Literature DB >> 6803845

The isolation, identification and characterization of sulfated glycosaminoglycans synthesized in vitro by human eosinophils.

D D Metcalfe, J Litvin, S I Wasserman.   

Abstract

Human eosinophils were purified to greater than 92% using 16-30% metrizamide gradients, and these cells cultured for up to 72 h in vitro to label sulfated glycosaminoglycans. Over 90% of the sulfated glycosaminoglycan-containing material was extracted in 4 M guanidine HCl and had a hydrodynamic size similar to a glycosaminoglycan marker with an approximate average molecular weight of 60,000. Treatment of this salt-extracted 35S-labeled glycosaminoglycan-containing material with 0.5 M NaOH resulted in a change in mass to approx. 20,000 daltons, suggesting that the larger molecules were proteoglycans with side chains with an approximate molecular weight of 20,000. These salt extracted presumptive 35S-labeled proteoglycans were protease insensitive and behaved in a highly charged fashion on DEAE-cellulose. The composition of 35S-labeled glycosaminoglycans from human eosinophils as identified using selected polysaccharides was 70-81% chondroitin 4-sulfate, 9-12% chondroitin 6-sulfate, and 5-12% dermatan sulfate. The predominance of chondroitin 4-sulfate in human eosinophils is similar to the predominance of chondroitin 4-sulfate in human neutrophils and human platelets.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803845     DOI: 10.1016/0304-4165(82)90359-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  An extragranular compartment of blood eosinophils contains eosinophil protein X/eosinophil-derived neurotoxin (EPX/EDN).

Authors:  Malgorzata Karawajczyk; Christer G B Peterson; Per Venge; Rodolfo C Garcia
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

2.  Metabolic properties of a homogeneous proteoglycan of a haemopoietic stem cell line, FDCP-mix.

Authors:  A J Morris; T M Dexter; J T Gallagher
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.